uniQure reports 48-month AMT-130 data for Huntington's disease gene therapy
The company presented updated Phase I/II results and safety findings on September 29, 2026, ahead of planned BLA and MAA submissions.
SEC filing
Latest
3 stories
Tuesday, September 29
Wednesday, September 2
uniQure files BLA and UK MAA for Huntington's gene therapy AMT-130
The September 2, 2026 filings seek accelerated U.S. approval and U.K. authorization for ifezuntirgene inilparvovec, backed by three-year Phase I/II data.
SEC filing
Wednesday, July 29
uniQure reaffirms Q3 2026 BLA plans for AMT-130 in Huntington's disease
The company says four-year Phase I/II data are expected in September 2026, alongside early AMT-260 epilepsy data and a $259 million raise extending its cash runway into 2030.
SEC filing